| scholarly article | Q13442814 |
| P50 | author | Stephen R. Rapp | Q124352318 |
| P2093 | author name string | Feldman SR | |
| Fleischer AB Jr | |||
| Exum ML | |||
| Reboussin DM | |||
| P2860 | cites work | Suicidal ideation in psoriasis | Q70588554 |
| Life events and psychological distress in dermatologic disorders: psoriasis, chronic urticaria and fungal infections | Q71326126 | ||
| Psychiatric symptoms in dermatology patients | Q71820642 | ||
| The self-administered psoriasis area and severity index is valid and reliable | Q34732726 | ||
| Obsessive-compulsive disorder in patients with chronic pruritic conditions: case studies and discussion | Q38470878 | ||
| Epidemiologic strategies in psoriasis research | Q40677354 | ||
| Patient measurement of psoriasis disease severity with a structured instrument | Q41032145 | ||
| The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis. | Q41638189 | ||
| Detection of depressive disorder for patients receiving prepaid or fee-for-service care. Results from the Medical Outcomes Study | Q43794858 | ||
| Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scores | Q43808624 | ||
| The annual cost of psoriasis. | Q50608149 | ||
| Interpersonal concerns and psychological difficulties of psoriasis patients: effects of disease severity and fear of negative evaluation. | Q51093092 | ||
| Aggression in depressives and psoriatics. | Q51226222 | ||
| Hostile personality characteristics, dysthymic states and neurotic symptoms in urticaria, psoriasis and alopecia. | Q51227716 | ||
| The Physical, Psychological and Social Impact of Psoriasis | Q61962832 | ||
| Skin disease and handicap: an analysis of the impact of skin conditions | Q67285117 | ||
| Psoriasis and stress | Q67708888 | ||
| Validation of Sickness Impact Profile and Psoriasis Disability Index in Psoriasis | Q68640564 | ||
| A psychocutaneous profile of psoriasis patients who are stress reactors. A study of 127 patients | Q69611559 | ||
| A study of depression and obsessionality in dysmorphophobic and psoriatic patients | Q70281820 | ||
| P433 | issue | 3 Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | disability | Q12131 |
| P304 | page(s) | 401-407 | |
| P577 | publication date | 1999-09-01 | |
| P1433 | published in | Journal of the American Academy of Dermatology | Q15757046 |
| P1476 | title | Psoriasis causes as much disability as other major medical diseases | |
| P478 | volume | 41 |
| Q43742824 | 'In someone's clinic but not in mine'--clinicians' views of supporting lifestyle behaviour change in patients with psoriasis: a qualitative interview study. |
| Q35020447 | 'On the surface': a qualitative study of GPs' and patients' perspectives on psoriasis |
| Q33242881 | A 308-nm monochromatic excimer light in the treatment of palmoplantar psoriasis |
| Q45930687 | A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients. |
| Q38912824 | A Novel Model for Predicting Incident Moderate to Severe Anemia and Iron Deficiency in Patients with Newly Diagnosed Ulcerative Colitis |
| Q47753359 | A cross-sectional survey of the nature and correlates of sleep disturbance in people with psoriasis |
| Q89823404 | A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models |
| Q37898704 | A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. |
| Q48081441 | A pilot study examining mindfulness-based cognitive therapy in psoriasis. |
| Q34156420 | A practical approach to monitoring patients on biological agents for the treatment of psoriasis |
| Q47445839 | A prospective cross-sectional study of anxiety and depression in patients with psoriasis in Singapore |
| Q44052184 | A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis |
| Q48023237 | A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasis |
| Q36222067 | A review of acitretin, a systemic retinoid for the treatment of psoriasis |
| Q35069963 | A study of awareness and screening behavior of cardiovascular risk factors in patients with psoriasis and dermatologists |
| Q35846824 | A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values |
| Q38840318 | A systematic review on methods used to evaluate patient preferences in psoriasis treatments |
| Q60683249 | Abordaje integral de la comorbilidad del paciente con psoriasis |
| Q90474122 | Acceptance of Illness, Satisfaction with Life, Sense of Stigmatization, and Quality of Life among People with Psoriasis: A Cross-Sectional Study |
| Q36176854 | Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People's Republic of China. |
| Q28082927 | Acupuncture for psoriasis: protocol for a systematic review |
| Q58434950 | Adalimumab for the treatment of severe psoriasis and psoriatic arthritis |
| Q59217938 | Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study |
| Q38127746 | Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis |
| Q51905812 | Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. |
| Q37901280 | Adherence in the treatment of psoriasis: a systematic review |
| Q47560483 | Adherence to biologics in patients with psoriasis |
| Q37628279 | Adherence to guidelines in the use of biological agents to treat psoriasis in Brazil |
| Q38042075 | Adherence to medication in patients with psoriasis: a systematic literature review. |
| Q36461970 | Adherence to treatment in patients with psoriasis. |
| Q37427086 | Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature |
| Q81354761 | Advances in psoriasis treatment |
| Q36648461 | Adverse events from systemic therapies for psoriasis are common in clinical practice. |
| Q46902217 | Alcohol consumption and psychological distress in patients with psoriasis |
| Q37946497 | Alcohol, psoriasis, liver disease, and anti-psoriasis drugs |
| Q45101688 | An Italian study on psoriasis and depression |
| Q34610829 | An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options |
| Q48022884 | An exploratory study using framework analysis to investigate health-seeking behaviour in patients with psoriasis |
| Q48515876 | Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients |
| Q34284377 | Antisense oligonucleotide treatments for psoriasis |
| Q88495313 | Análisis Costo-Utilidad Del Uso De Adalimumab, Etanercept E Infliximab Para El Tratamiento De La Artritis Psoriásica En Uruguay |
| Q37998917 | Application of the dermatology life quality index in clinical trials of biologics for psoriasis |
| Q33261650 | Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence |
| Q36942993 | Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis |
| Q38930229 | Aquaporins in the Skin |
| Q33831065 | Assessing long-term drug safety: lessons (re) learned from raptiva. |
| Q48650579 | Assessing quality of life in patients with psoriasis and its improvement with treatment. |
| Q92616693 | Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response |
| Q55153984 | Assessment and monitoring of biologic drug adverse events in patients with psoriasis. |
| Q47363049 | Assessment of Quality of Life in Patients With Skin Disorders Undergoing Ayurvedic Panchakarma (Biopurification) as Management |
| Q53417833 | Assessment of depression in subjects with psoriasis vulgaris and lichen planus. |
| Q47862404 | Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis. |
| Q34050825 | Association between Psoriasis and Cardiovascular Risk Factors in Korean Patients |
| Q47099370 | Associations between body mass index and severity of psoriasis |
| Q58812305 | Atherosclerosis as a systemic feature of psoriasis |
| Q43881110 | Attentional bias for psoriasis-specific and psychosocial threat in patients with psoriasis |
| Q47441368 | Balneotherapy in Psoriasis Rehabilitation |
| Q44943391 | Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis--a multinational cross-sectional study. |
| Q45129897 | Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: Comparison of adverse event–free response days in the CHAMPION trial |
| Q42403229 | Beyond skin: the need for a new approach to the management of psoriasis in primary care |
| Q64106987 | Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? |
| Q36471426 | Biological therapy for psoriasis |
| Q48070433 | Biologics are more potent than other treatment modalities for improvement of quality of life in psoriasis patients |
| Q24235424 | Biologics for chronic plaque psoriasis |
| Q24242281 | Biologics for chronic plaque psoriasis |
| Q52651099 | Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future. |
| Q37416210 | Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab |
| Q58113562 | Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics |
| Q34351604 | Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece |
| Q26747639 | Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective |
| Q47623918 | Burden of chronic urticaria relative to psoriasis in five European countries |
| Q37519631 | Burden of skin diseases |
| Q48227997 | Carboxytherapy for treatment of localized chronic plaque psoriasis: Clinical and histopathologic evaluation |
| Q37145684 | Cardiometabolic risk in psoriasis: differential effects of biologic agents |
| Q39412708 | Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin |
| Q44631637 | Case studies in severe psoriasis: A clinical strategy |
| Q34296816 | Challenges for synthesising data in a network of registries for systemic psoriasis therapies |
| Q21245614 | Characterizing the burden of premature ejaculation from a patient and partner perspective: a multi-country qualitative analysis |
| Q58057465 | Chronic disease influences over 40 major life-changing decisions (MLCDs): a qualitative study in dermatology and general medicine |
| Q51702236 | Chronic diseases influence major life changing decisions: a new domain in quality of life research. |
| Q41318563 | Chronic stress experience and burnout syndrome have appreciable influence on health-related quality of life in patients with psoriasis |
| Q36069539 | Class I topical corticosteroid use by psoriasis patients in an academic practice |
| Q36163428 | Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis |
| Q40389803 | Clinical efficacy of platelet rich plasma in combination with methotrexate in chronic plaque psoriatic patients |
| Q41053849 | Clinical symptoms and self-reported disease severity among patients with psoriasis - Implications for psoriasis management |
| Q41378761 | Clinical trials in dermatology |
| Q36640532 | Clinical, Quality of Life, Patient Adherence, and Safety Outcomes of Short-Course (12 Weeks) Treatment with Cyclosporine in Patients with Severe Psoriasis (the Practice Study). |
| Q36222073 | Clobetasol propionate foam in the treatment of psoriasis. |
| Q90261441 | Cohort profile: the clinical 'Psoriasis in Adolescents' (PIA) cohort in Denmark |
| Q37630778 | Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory Study |
| Q40404895 | Communicating Cardiovascular Disease Risk to People with Psoriasis: What Techniques do Practitioners Use? |
| Q48072913 | Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: a cross-sectional study (Arizona study). |
| Q40261663 | Comparative effectiveness of biologic therapies on improvements in quality of life in patients with psoriasis. |
| Q36334747 | Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. |
| Q36033361 | Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment |
| Q57159144 | Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials |
| Q41008261 | Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician's Global Assessment, Psoriasis Area and Severity Index and Static Phy |
| Q31029459 | Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis |
| Q53201470 | Consumer Quality Index Chronic Skin Disease (CQI-CSD): a new instrument to measure quality of care from the patient's perspective. |
| Q46210972 | Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis |
| Q47647524 | Cost-Effectiveness Analysis of Ixekizumab vs Etanercept and Their Manufacturer-Recommended Dosing Regimens in Moderate to Severe Plaque Psoriasis |
| Q36376401 | Cost-effectiveness of moderate-to-severe psoriasis treatment. |
| Q33296076 | Cost-effectiveness of psoriasis therapy with etanercept in Germany |
| Q50799850 | Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. |
| Q38039491 | Current and emerging systemic treatment strategies for psoriasis |
| Q34112840 | Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents |
| Q47637078 | DLQI as a major criterion for introduction of systemic agents in patients with mild psoriasis |
| Q48073724 | Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI). |
| Q36988833 | Depression and Insomnia in Patients With Psoriasis and Psoriatic Arthritis Taking Tumor Necrosis Factor Antagonists |
| Q37566094 | Depression and quality of life in psoriasis |
| Q38839027 | Dermatological comorbidity in psoriasis: results from a large-scale cohort of employees |
| Q53253693 | Developing a quality of life instrument in patients with psoriasis: the Psoriasis Quality of Life Questionnaire (PQLQ). |
| Q24673687 | Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis |
| Q34424519 | Development of the US PSORIQoL: a psoriasis-specific measure of quality of life |
| Q33548150 | Differing effect of systemic anti psoriasis therapies on platelet physiology--a case report and review of literature |
| Q50731986 | Diminished neural and cognitive responses to facial expressions of disgust in patients with psoriasis: a functional magnetic resonance imaging study. |
| Q58764407 | Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos |
| Q64122005 | Disease Burden and Treatment Patterns of Psoriasis in Russia: A Real-World Patient and Dermatologist Survey |
| Q35892185 | Distribution pattern of psoriasis, anxiety and depression as possible causes of sexual dysfunction in patients with moderate to severe psoriasis |
| Q36939785 | Do utilization management controls for phototherapy increase the prescription of biologics? |
| Q38023581 | Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis? |
| Q47224549 | Double trouble: psoriasis and cardiometabolic disorders. |
| Q53511266 | Dowling Oration 2000. Dermatology patients: what do they really need? |
| Q44456581 | Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab |
| Q40902492 | Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study |
| Q48641201 | Dyadic adjustment, family coping, body image, quality of life and psychological morbidity in patients with psoriasis and their partners |
| Q48351106 | Economic burden of moderate to severe plaque psoriasis in Canada |
| Q47450243 | Efalizumab for psoriasis? |
| Q44124198 | Efalizumab in routine use: a clinical experience |
| Q58404187 | Efalizumab in the Treatment of Psoriasis |
| Q84466029 | Efalizumab in the treatment of psoriasis |
| Q39477242 | Effect of Adalimumab on Gene Expression Profiles of Psoriatic Skin and Blood |
| Q38285771 | Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. |
| Q37053038 | Effect of store and forward teledermatology on quality of life: a randomized controlled trial |
| Q33687980 | Effects of Topical Application of Betamethasone on Imiquimod-induced Psoriasis-like Skin Inflammation in Mice |
| Q33713076 | Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials. |
| Q44554932 | Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study |
| Q41957838 | Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: a meta-analysis and cost-efficacy analysis using the intention-to-treat principle |
| Q38365042 | Efficacy and safety of emerging immunotherapies in psoriasis. |
| Q92084148 | Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis |
| Q37743492 | Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis |
| Q37592632 | Efficacy of adding topical simvastatin to topical calcipotriol on improvement of cutaneous plaque psoriasis |
| Q34190076 | Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment |
| Q48065188 | Efficacy, tolerability and safety of switching from etanercept to infliximab for the treatment of moderate-to-severe psoriasis: A multicenter, open-label trial (TANGO). |
| Q47754478 | Elevated prevalence of Type D (distressed) personality in moderate to severe psoriasis is associated with mood status and quality of life impairment: a comparative pilot study |
| Q30984470 | Emerging drugs for moderate-to-severe psoriasis |
| Q36179686 | Emerging drugs in psoriasis |
| Q37857668 | Emerging treatments in the management of psoriasis: biological targeting with ustekinumab |
| Q48163947 | Epidemiological survey of patients with psoriasis in Matsumoto city, Nagano Prefecture, Japan. |
| Q46806771 | Epidemiology of moderate-to-severe plaque psoriasis in a Canadian surveyed population. |
| Q36481432 | Epidemiology of psoriasis. Review and the German perspective |
| Q90151230 | Erbium-doped Yttrium Aluminium Garnet (Er:YAG) Laser Resurfacing Restores Normal Function and Cosmesis in Patients with Severe Rhinophyma |
| Q39303337 | Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control |
| Q34450544 | Etanercept in psoriasis: the evidence of its therapeutic impact. |
| Q34570738 | European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey |
| Q92236572 | Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis |
| Q35190112 | Evaluation and management of psoriatic arthritis: the role of biologic therapy |
| Q33673930 | Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis |
| Q48381880 | Evaluation of the impact of writing exercises interventions on quality of life in patients with psoriasis undergoing systemic treatments |
| Q52925161 | Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. |
| Q35866830 | Evolution of Cooperation Patterns in Psoriasis Research: Co-Authorship Network Analysis of Papers in Medline (1942-2013). |
| Q38838470 | Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region. |
| Q26778531 | Exploring the Physiological Link between Psoriasis and Mood Disorders |
| Q40267949 | Extent of misconceptions, negative prejudices and discriminatory behaviour to psoriasis patients in France |
| Q48038663 | Factors Predicting Testing and Treatment of Iron Deficiency in a Nationwide Cohort of Anemic UC Patients |
| Q38306698 | Fatigue in psoriasis: a phenomenon to be explored |
| Q43645804 | Fumaderm® in daily practice for psoriasis: dosing, efficacy and quality of life |
| Q54958047 | Fumaric acid esters in the management of psoriasis. |
| Q79204592 | Functional disability and quality of life in patients with ankylosing spondylitis |
| Q48480123 | German S3-guidelines on the treatment of psoriasis vulgaris (short version). |
| Q35875481 | German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). |
| Q26991871 | Global epidemiology of psoriasis: a systematic review of incidence and prevalence |
| Q38001059 | Guidance on the diagnosis and clinical management of psoriasis |
| Q38557350 | Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials. |
| Q92485497 | Guselkumab for the treatment of psoriasis - evidence to date |
| Q92551084 | Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial |
| Q53835593 | Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. |
| Q53051911 | Health-related quality of life in patients with psoriasis. |
| Q38853236 | Health-related quality of life in patients with psoriasis: a systematic review of the European literature |
| Q48580332 | Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases |
| Q37724932 | Hope as a Psychological Factor Affecting Quality of Life in Patients With Psoriasis |
| Q37670632 | How does stigma affect people with psoriasis? |
| Q91993172 | How frequently does palmoplantar psoriasis affect the palms and/or soles? A systematic review and meta-analysis |
| Q37665294 | How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review |
| Q36921945 | How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center. |
| Q38111443 | IL-17 targeted therapies for psoriasis |
| Q34497024 | Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study |
| Q38912240 | Immunotargeting in the management of psoriasis |
| Q35862134 | Impact of Baseline Disease Severity Over 26 and 52 Weeks of Treatment with Calcitriol Ointment 3µg/g in Patients with Mild-to-moderate Plaque Psoriasis |
| Q34349903 | Impact of Psoriasis on Quality of Life: Relationship between Clinical Response to Therapy and Change in Health-related Quality of Life |
| Q25256974 | Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. |
| Q34615309 | Impact of postthyroidectomy scar on the quality of life of thyroid cancer patients |
| Q59809055 | Impact of psoriasis in the quality of life of children, adolescents and their families: a cross-sectional study |
| Q47597260 | Impact of psoriasis on quality of life in Kuwait |
| Q48469656 | Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase 2 / 3 trial |
| Q51917360 | Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. |
| Q49154119 | Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study |
| Q34071641 | In psoriasis, levels of hope and quality of life are linked |
| Q27007133 | Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis |
| Q37717832 | Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study |
| Q40289807 | Increasing prevalence but not incidence of psoriasis in the U.K. |
| Q38828910 | Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries |
| Q24188256 | Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis |
| Q36374589 | Infliximab for inpatient psoriasis management--is there a role? |
| Q33371653 | Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study |
| Q37307554 | Infliximab for the treatment of plaque psoriasis. |
| Q36541961 | Infliximab for the treatment of psoriasis |
| Q35636983 | Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis |
| Q35555905 | Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial |
| Q34620291 | Infliximab in the treatment of plaque type psoriasis |
| Q35752518 | Influence of Psoriasis on Household Chores and Time Spent on Skin Care at Home: A Questionnaire Study |
| Q93508292 | Introduction |
| Q33903607 | Introduction. The magnitude of skin disease in the United States |
| Q99416979 | Investigation of predictors of interest in a brief mindfulness-based intervention and its effects in patients with psoriasis at a rehabilitation clinic (SkinMind): an observational study and randomised controlled trial |
| Q37956733 | Investigational VEGF antagonists for psoriasis |
| Q33858767 | Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: A systematic and critical review |
| Q98464718 | Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study) |
| Q48315122 | Low-dose, short-term ciclosporin (Neoral®) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients |
| Q49715919 | L’agora du psoriasis : histoire, actualités et questionnements |
| Q53828883 | Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. |
| Q37930978 | Management of psoriatic arthritis from the view of the dermatologist |
| Q54941753 | Management of scalp psoriasis: current perspectives. |
| Q39274236 | Management of the psychological comorbidities of dermatological conditions: practitioners' guidelines. |
| Q40114903 | Managing Mild-to-Moderate Psoriasis in Elderly Patients: Role of Topical Treatments. |
| Q27693878 | Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis |
| Q37867174 | Maximizing patient adherence for optimal outcomes in psoriasis |
| Q38072725 | Measurement of health-related quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life |
| Q48123615 | Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. |
| Q51918693 | Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. |
| Q91894657 | Mesenchymal Stem Cells Alleviate Moderate-to-Severe Psoriasis by Reducing the Production of Type I Interferon (IFN-I) by Plasmacytoid Dendritic Cells (pDCs) |
| Q98164399 | Metagenomic analysis of gut microbiota in non-treated plaque psoriasis patients stratified by disease severity: development of a new Psoriasis-Microbiome Index |
| Q88205381 | Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study |
| Q36823606 | Moderate and severe plaque psoriasis: cost-of-illness study in Italy |
| Q37610764 | Molecular dissection of psoriasis: integrating genetics and biology |
| Q45977850 | Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. |
| Q41967507 | More Biologic Therapies Expected To Treat Advanced Plaque Psoriasis |
| Q48097390 | Nail Psoriasis, the unknown burden of disease |
| Q26753038 | Nail Psoriasis: A Review of Treatment Options |
| Q37153882 | Neutrophil extracellular trap formation is increased in psoriasis and induces human β-defensin-2 production in epidermal keratinocytes |
| Q89621631 | New and Emerging Topical Therapies for Psoriasis and Atopic Dermatitis |
| Q37846678 | New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab |
| Q36502882 | New treatments for psoriasis: which biologic is best? |
| Q38935474 | No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. |
| Q34024439 | Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation. |
| Q44506458 | Non-thermal atmospheric plasma ameliorates imiquimod-induced psoriasis-like skin inflammation in mice through inhibition of immune responses and up-regulation of PD-L1 expression |
| Q98945342 | Nonadherence to Treatment and Patient-Reported Outcomes of Psoriasis During the COVID-19 Epidemic: A Web-Based Survey |
| Q38728552 | Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis |
| Q26827714 | Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy |
| Q24187957 | Oral fumaric acid esters for psoriasis |
| Q24198185 | Oral fumaric acid esters for psoriasis |
| Q34433768 | Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial |
| Q37345488 | Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study |
| Q38767538 | PGRN Suppresses Inflammation and Promotes Autophagy in Keratinocytes Through the Wnt/β-Catenin Signaling Pathway |
| Q34194956 | Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis |
| Q36894005 | Pathogenesis and clinical features of psoriasis |
| Q44365951 | Patient reports of the frequency and severity of adverse reactions associated with biological agents prescribed for psoriasis in Brazil |
| Q47877368 | Patient-relevant treatment goals in psoriasis |
| Q38354062 | Patient-reported outcome measures in psoriasis: the good, the bad and the missing! |
| Q34196035 | Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting |
| Q48644097 | Patient-reported outcomes in psoriasis research and practice. |
| Q92556095 | Patients with psoriasis have a higher risk of schizophrenia: A systematic review and meta-analysis of observational studies |
| Q48086297 | Patients with psoriasis have insufficient knowledge of their risk of atherothrombotic disease and metabolic syndrome |
| Q39165009 | Patients' perspectives in the management of psoriasis: the Italian results of the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. |
| Q44033156 | Patients' strategies for coping with psoriasis |
| Q35752528 | Perceptions on the Psychological Impact of Facial Erythema Associated with Rosacea: Results of International Survey |
| Q85743931 | Perspective: Don't be superficial |
| Q45935239 | Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. |
| Q56797850 | Phase II randomized, placebo-controlled trial of M. vaccae-derived protein (PVAC®) for the treatment of psoriasis |
| Q36005460 | Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life tool |
| Q44288342 | Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp |
| Q53168250 | Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials. |
| Q51092732 | Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis. |
| Q55141743 | Positive effects of hydrogen-water bathing in patients of psoriasis and parapsoriasis en plaques. |
| Q96303803 | Possible Role of Phosphatidylglycerol-Activated Protein Kinase C-βII in Keratinocyte Differentiation |
| Q34995244 | Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options |
| Q50955290 | Presentation of psoriatic arthritis in the literature: a twenty-year bibliometric evaluation. |
| Q40714818 | Prevalence and Associated Factors of Erectile Dysfunction in Patients With Moderate to Severe Psoriasis and Healthy Population: A Comparative Study Considering Physical and Psychological Factors |
| Q39064240 | Prevalence of weight loss attempts and behaviors used by individuals with psoriasis in the United States population |
| Q43263272 | Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care? |
| Q24598008 | Promising new treatments for psoriasis |
| Q92964054 | Protocol for a case-control diagnostic accuracy study to develop diagnostic criteria for psoriasis in children (DIPSOC study): a multicentre study recruiting in UK paediatric dermatology clinics |
| Q64981157 | PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study. |
| Q48616775 | Psodisk, a new visual method for assessing the burden of psoriasis on patients |
| Q56115291 | Psoriasis |
| Q64058521 | Psoriasis Pathogenesis and Treatment |
| Q40329572 | Psoriasis and cardiovascular events: updating the evidence. |
| Q30235889 | Psoriasis and comorbid diseases: Epidemiology |
| Q34997840 | Psoriasis and its management |
| Q37676220 | Psoriasis and its treatment with adalimumab. |
| Q38443811 | Psoriasis and psycho-dermatology |
| Q51800505 | Psoriasis and sport: a new ally? |
| Q51415136 | Psoriasis and the Digital Landscape: YouTube as an Information Source for Patients and Medical Professionals. |
| Q48102426 | Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink |
| Q39967628 | Psoriasis and the liver: problems, causes and course |
| Q35579443 | Psoriasis assessment tools in clinical trials |
| Q37084274 | Psoriasis comorbidities |
| Q48457183 | Psoriasis following bariatric surgery: clinical evolution and impact on quality of life on 10 patients |
| Q40219748 | Psoriasis has a major secondary impact on the lives of family members and partners |
| Q47669886 | Psoriasis in patients older than 65 years. A comparative study with younger adult psoriatic patients. |
| Q47830025 | Psoriasis pathogenesis and the development of novel targeted immune therapies. |
| Q38260967 | Psoriasis treatment and management - a systematic review of full economic evaluations |
| Q35579427 | Psoriasis treatment: current and emerging directed therapies |
| Q43720323 | Psoriasis uncovered--measuring burden of disease impact in a survey of Australians with psoriasis |
| Q38692102 | Psoriasis, Depression, and Inflammatory Overlap: A Review |
| Q26744032 | Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? |
| Q37224763 | Psoriasis--new insights into pathogenesis and treatment |
| Q38981907 | Psoriasis: The Poster Child for Bench-to-bedside Translational Medicine. |
| Q53504190 | Psoriasis: a possible risk factor for development of coronary artery calcification. |
| Q37139136 | Psoriasis: characteristics, psychosocial effects and treatment options |
| Q42981137 | Psoriasis: characteristics, psychosocial effects and treatment options |
| Q28088340 | Psoriasis: classical and emerging comorbidities |
| Q37233759 | Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment |
| Q36028220 | Psoriasis: emerging therapeutic strategies |
| Q43191547 | Psoriasis: impact and management of moderate to severe disease |
| Q48708208 | Psoriasis: is it the tip of the iceberg for the quality of life of patients and their families? |
| Q22306121 | Psoriasis: symptoms, treatments and its impact on quality of life |
| Q35902691 | Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist. |
| Q38078340 | Psychiatric evaluation in dermatology: an overview |
| Q38220340 | Psychodermatological aspects of atopic dermatitis |
| Q40017163 | Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis |
| Q34131556 | Psychosocial effect of common skin diseases |
| Q47823378 | Psychosocial morbidity in skin disease. |
| Q48566723 | Qualitative assessment of the content validity of the Dermatology Life Quality Index in patients with moderate to severe psoriasis |
| Q43446877 | Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study |
| Q36398293 | Quality of life and psychosocial aspects in Greek patients with psoriasis: a cross-sectional study |
| Q48064273 | Quality of life and related factors in a cohort of plaque-type psoriasis patients in La Coruña, Spain |
| Q51503044 | Quality of life and sexual health in patients with genital psoriasis. |
| Q53430430 | Quality of life in 6497 Nordic patients with psoriasis. |
| Q34810851 | Quality of life in cutaneous lupus erythematosus |
| Q37444029 | Quality of life in patients with bullous dermatoses |
| Q21245617 | Quality of life in patients with psoriasis |
| Q48129347 | Quality of life in patients with vitiligo using the Short Form-36. |
| Q38211301 | Quality of life in psoriasis patients |
| Q35190085 | Quality of life issues in psoriasis |
| Q51069932 | Quality of life of psoriasis patients. |
| Q38558139 | Quality of life: a research gap in teledermatology |
| Q37196004 | Radiographic and functional outcomes after displaced intra-articular calcaneal fractures: a comparative cohort study among the traditional open technique (ORIF) and percutaneous surgical procedures (PS). |
| Q38907492 | Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. |
| Q92942644 | Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America |
| Q48085635 | Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: 4- and 12-week interim results from the PRO-long study |
| Q37309074 | Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study |
| Q55515872 | Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization |
| Q40209526 | Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden. |
| Q41722722 | Relationship between Helicobacter pylori infection and psoriasis. |
| Q97520017 | Reliability and validity of the Chinese version of the Patient Health Questionnaire-9 (C-PHQ-9) in patients with psoriasis: a cross-sectional study |
| Q48229893 | Review of the mechanism of action of coal tar in psoriasis |
| Q87736667 | Risk of Cardiovascular Outcomes among Psoriasis Patients Treated with Biologics and Other Systemic Agents |
| Q38983615 | Risk of depression in women with psoriasis: a cohort study |
| Q38408788 | Risk of self-harm and nonfatal suicide attempts, and completed suicide in patients with psoriasis: a population-based cohort study |
| Q37712237 | Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab |
| Q52888818 | S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. |
| Q48053421 | SF-36 healty survey on psoriasis quality-of-life: a study of 414 Taiwanese patients. |
| Q58694680 | Secukinumab in the treatment of psoriasis: patient selection and perspectives |
| Q36746549 | Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial |
| Q36470420 | Self-management in daily life with psoriasis: an integrative review of patient needs for structured education |
| Q24800272 | Self-reported health-related quality of life in persons with HIV infection: results from a multi-site interview project |
| Q46731189 | Serious infections among a large cohort of subjects with systemically treated psoriasis |
| Q43934804 | Serum lipids and apolipoproteins in patients with psoriasis |
| Q53136638 | Severity levels in psoriasis: a separate 'very severe' category not required. |
| Q38271359 | Sexual dysfunction in psoriasis: a systematic review. |
| Q47674064 | Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional study. |
| Q48695846 | Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. |
| Q39570026 | Skin disease is common in rural Nepal: results of a point prevalence study |
| Q46818451 | Social problem-solving, perceived stress, negative life events, depression and life satisfaction in psoriasis |
| Q38829783 | Socioeconomic and sociocultural determinants of psychological distress and quality of life among patients with psoriasis in a selected multi-ethnic Malaysian population. |
| Q52716685 | Soy Phosphatidylglycerol Reduces Inflammation in a Contact Irritant Ear Edema Mouse Model in vivo. |
| Q54441487 | Specialized dermatological care for marginalized populations and education at the primary care level: is community dermatology a feasible proposal? |
| Q59809320 | Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date |
| Q35207586 | Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost |
| Q37893691 | Stress and quality of life in psoriasis: an update |
| Q34025504 | Sun exposure induces rapid immunological changes in skin and peripheral blood in patients with psoriasis |
| Q38097729 | Systematic review of UV-based therapy for psoriasis |
| Q38283299 | Systematic review of cost-effectiveness analyses of treatments for psoriasis |
| Q24188334 | Systemic pharmacological treatments for chronic plaque psoriasis |
| Q47260366 | Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. |
| Q35554338 | TNFalpha therapy in psoriatic arthritis and psoriasis |
| Q40543657 | TUR-PSO: A cross-sectional, study investigating quality of life and treatment status of psoriasis patients in Turkey |
| Q37626774 | Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease |
| Q93076415 | Tetrandrine inhibits the proliferation and cytokine production induced by IL-22 in HaCaT cells |
| Q36059239 | The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries |
| Q33572834 | The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives |
| Q64241342 | The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab |
| Q36771864 | The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis |
| Q39390195 | The Importance of Skin Disease as Assessed by “Willingness-To-Pay” |
| Q36032317 | The Pattern of Psoriatic Arthritis in Kashmir: A 6-Year Prospective Study. |
| Q48266852 | The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument |
| Q36436098 | The Relationship between Disease, Work and Sickness Absence among Psoriasis Patients |
| Q87330456 | The Role of Acupuncture in Pain Management |
| Q39074683 | The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis |
| Q39835642 | The association of dermatologist-diagnosed and self-reported skin diseases with skin-related quality of life in Latino migrant farmworkers |
| Q38044995 | The burden of moderate to severe psoriasis: an overview |
| Q48903362 | The burden of skin disease: quality of life, economic aspects and social issues. |
| Q36374594 | The comorbid state of psoriasis patients in a university dermatology practice. |
| Q59527926 | The content validity of the PSS in patients with plaque psoriasis |
| Q47580580 | The contribution of perceptions of stigmatisation to disability in patients with psoriasis |
| Q36391439 | The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. |
| Q44647501 | The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey |
| Q39358289 | The experience of having psoriasis through the lens of the International Classification of Functioning, Disability and Health (ICF). |
| Q38644022 | The impact of disease severity, illness beliefs and coping strategies on outcomes in psoriatic arthritis. |
| Q58698647 | The impact of genital psoriasis on quality of life: a systematic review |
| Q34609632 | The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups |
| Q35230117 | The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients |
| Q50091508 | The journey of adult psoriasis patients towards biologics: past and present - Results from the BioCAPTURE registry |
| Q37722744 | The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. |
| Q39064616 | The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis. |
| Q26862537 | The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis |
| Q37101746 | The psychosocial and occupational impact of chronic skin disease |
| Q34156429 | The rationale behind topical vitamin d analogs in the treatment of psoriasis: where does topical calcitriol fit in? |
| Q26771882 | The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal disease |
| Q37327150 | The role of focal infections in the pathogenesis of psoriasis and chronic urticaria |
| Q38979741 | The role of personal models in clinical management: Exploring health care providers' beliefs about psoriasis. |
| Q37706606 | The use of ustekinumab in autoimmune disease. |
| Q38098466 | Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents |
| Q33651502 | Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial |
| Q48770670 | Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. |
| Q48322904 | Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis |
| Q34479570 | Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial |
| Q48059175 | Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial |
| Q48448233 | Tomesa balneophototherapy in mild to severe psoriasis: a retrospective clinical trial in 174 patients |
| Q27003961 | Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses |
| Q37766897 | Topical treatment of psoriasis |
| Q24186104 | Topical treatments for scalp psoriasis |
| Q34612724 | Tracking dynamic microvascular changes during healing after complete biopsy punch on the mouse pinna using optical microangiography. |
| Q38543325 | Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments |
| Q34956195 | Treatment and referral patterns for psoriasis in United Kingdom primary care: a retrospective cohort study |
| Q34076641 | Treatment costs of psoriasis in a tertiary-level clinic. |
| Q38075023 | Treatment goals for moderate to severe psoriasis: an Australian consensus. |
| Q36870158 | Treatment goals in psoriasis |
| Q33412410 | Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials |
| Q38132706 | Treatment of psoriasis and psoriatic arthritis |
| Q38207916 | Treatment of psoriasis: focus on clinic-based management with infliximab |
| Q37098135 | Treatment of severe psoriasis with infliximab |
| Q37660470 | Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines. |
| Q34620375 | Update of the management of chronic psoriasis: new approaches and emerging treatment options. |
| Q51189512 | Updates from the British Association of Dermatologists 91st annual meeting, 5-7 July 2011, London, U.K. |
| Q91905971 | Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients? |
| Q48160760 | Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey |
| Q48588135 | Use of digital infrared imaging in the assessment of childhood psoriasis |
| Q47913639 | Ustekinumab |
| Q37855945 | Ustekinumab for the treatment of psoriasis. |
| Q41244090 | Ustekinumab treatment in patients with psoriasis undergoing hemodialysis |
| Q37523846 | Ustekinumab: a new option in psoriasis therapy |
| Q34041797 | Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis |
| Q22305863 | Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis |
| Q41326716 | What is beauty?: Royal Victoria Hospital, Wednesday 1st October 2008. |
| Q84033687 | [A decade of biologics in dermatology] |
| Q84324579 | [A new view of psoriasis] |
| Q83200986 | [Co-morbidities in psoriasis vulgaris] |
| Q84279858 | [Comorbidities in psoriasis] |
| Q83887847 | [Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology] |
| Q81141986 | [Infliximab. Role in the treatment of psoriasis] |
| Q83444194 | [Physician and patient perception of disease severity, quality of life, and treatment satisfaction in psoriasis: an observational study in Spain] |
| Q81402808 | [Psychosocial consequences of psoriasis--an empirical study of disease burden in 3753 affected people] |
| Q52928363 | [S3-Guidelines for the therapy of psoriasis vulgaris]. |
| Q81380067 | [Therapeutic benefits in dermatological therapy. Evaluation of therapy from the physician's und patient's perspective in psoriasis and atopic dermatitis] |
| Q81817282 | [What are the objectives of moderate to severe psoriasis treatment?] |
Search more.